Promising results for CML
Tuesday, 09 December, 2008
Melbourne’s ChemGenex has released interim data of its Phase II/III trial of a compound for chronic myeloid leukaemia.
The trial involves 44 patients with the T315I mutation who have not responded to Novartis’ Glivec, or imatinib.
ChemGenex’s compound, omacetaxine mepesuccinate, showed good responses in chronic phase patients and was well tolerated, the company said.
The trial results were reported by trial investigator Jorge Cortes of the MD Anderson Cancer Center at a haematology conference in the US.
ChemGenex CEO Dr Greg Collier said the data would probably form part of the clinical section of the company’s new drug application to the US FDA next year.
Overuse of inhalers can increase heart attack risk
Overuse of reliever inhalers is associated with higher risks of developing and dying from...
Unhealthy Western diet could accelerate cognitive decline
An unhealthy Western-style diet is associated with a faster cognitive decline in people with a...
Cancer drug enters clinical trials based on a false mechanism
A cancer drug currently being tested in patients appears to have entered clinical trials based on...
